Cargando…
Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
BACKGROUND: Immune checkpoint inhibitors (ICIs) such as programmed cell death protein-1 (PD-1) inhibitors or PD-1 ligand-1 (PD-L1) inhibitors have led to remarkable improvement in outcomes of non-small cell lung cancer (NSCLC). Unfortunately, the significant benefits of ICI therapy are frequently li...
Autores principales: | Sarkar, Joy, Cortes Gomez, Eduardo, Oba, Takaaki, Chen, Hongbin, Dy, Grace K., Segal, Brahm H., Ernstoff, Marc S., Ito, Fumito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284636/ https://www.ncbi.nlm.nih.gov/pubmed/37350807 http://dx.doi.org/10.14740/wjon1587 |
Ejemplares similares
-
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
por: Yamauchi, Takayoshi, et al.
Publicado: (2021) -
Predictive and Prognostic Implications of Circulating CX3CR1(+) CD8(+) T Cells in Non–Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy
por: Abdelfatah, Eihab, et al.
Publicado: (2023) -
Gut microbiome and checkpoint inhibitor colitis
por: Sehgal, Kanika, et al.
Publicado: (2021) -
Gut microbiome in modulating immune checkpoint inhibitors
por: Li, Xiang, et al.
Publicado: (2022) -
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
por: Agrawal, Nikhil, et al.
Publicado: (2019)